The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer
Open accessAbstract
Purpose: We aimed at investigating the efficacy, tolerability, and quality of life (QOL) of gemcitabine (GEM) compared with pegylated liposomal doxorubicin (PLD) in the salvage treatment of recurrent ovarian cancer. Patients and Methods: A phase III randomized multicenter trial was planned to compare GEM (1,000 mg/m 2 on days 1, 8, and 15 every 28 days) with PLD (40 mg/m 2 every 28 days) in ovarian cancer patients who experienced treatment failure with only one platinum/paclitaxel regimen and who experienced recurrence or progression within 12 months after completion of primary treatment. Results: One hundred fifty-three patients were randomly assigned to PLD (n = 76) or GEM (n = 77). Treatment arms were well balanced for clinicopathologic characteristics. Grade 3 or 4 neutropenia was more frequent in GEM-treated patients versus PLD-treated patients (P = .007). Grade 3 or 4 palmar-plantar erythrodysesthesia was documented in a higher proportion of PLD patients (6%) versus GEM patients (0%; P = .061). The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056). No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411). However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm, although the P value was of borderline statistical significance (P = .048). Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments. Conclusion: GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., & Thun, M. J. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.2.106 · Cited by 5,314
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211
Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G., Kimmig, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0913 · Cited by 754
Mutch, D. G., Orlando, M., Goss, T., Teneriello, M. G., Gordon, A. N., McMeekin, S. D., Wang, Y., Scribner, D. R., Marciniack, M., Naumann, R. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6735 · Cited by 426
Gordon, A. N., Tonda, M., Sun, S., & Rackoff, W. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.07.011 · Cited by 422
Eisenkop, S. M., Spirtos, N. M., Friedman, R. L., Lin, W.-C. M., Pisani, A. L., & Perticucci, S. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00278-6 · Cited by 410
Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease
Armstrong, D. K. (2002) · The Oncologist · doi:10.1634/theoncologist.7-suppl_5-20 · Cited by 303
Systemic Therapy for Ovarian Cancer: Current Status and New Treatments
Ozols, R. F. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.03.011 · Cited by 188
Markman, M., KENNEDY, A. W., Webster, K. D., Peterson, G., Kulp, B., & Belinson, J. L. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.5921 · Cited by 155
Huinink, W. W. T. B., Lane, S. R., & Ross, G. A. (2003) · Annals of Oncology · doi:10.1093/annonc/mdh025 · Cited by 124
Rose, P. G., Maxson, J. H., Fusco, N. L., Mossbruger, K., & Rodriguez, M. J. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6272 · Cited by 108
The Clinical Utility of Liposomal Doxorubicin in Recurrent Ovarian Cancer
Campos, S. M., Penson, R. T., Mays, A. R., Berkowitz, R. S., Fuller, A. F., Goodman, A., Matulonis, U. A., Muzikansky, A., & Seiden, M. V. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2000.5980 · Cited by 107
Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer
D’Agostino, G., Amant, F. C., Berteloot, P., Scambia, G., & Vergote, I. B. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00011-8 · Cited by 103
Self-citationSmith, D. H., Adams, J. R., Johnston, S. R. D., Gordon, A., Drummond, M., & Bennett, C. L. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf275 · Cited by 76
Current Concepts of Treatment Strategies in Advanced or Recurrent Ovarian Cancer
Salzberg, M. O., Thurlimann, B. J. K., Bonnefois, H., Fink, D. A., Rochlitz, C. F., von Moos, R., & Senn, H.-J. (2005) · Oncology · doi:10.1159/000086967 · Cited by 63
The current treatment of recurrent ovarian cancer
Herzog, T. J. (2006) · Current Oncology Reports · doi:10.1007/s11912-006-0074-9 · Cited by 60
Kim, R. J., Peterson, G., Kulp, B., Zanotti, K. M., & Markman, M. M. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.12.057 · Cited by 47
Sehouli, J., Oskay-Özcelik, G., Kuhne, J. F., Stengel, D., Hindenburg, H.-J., Klare, P., Heinrich, G., Schmalfeldt, B., Mertens, H., Camara, O., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl079 · Cited by 31
Cited by
Recent progress in the diagnosis and treatment of ovarian cancer
Jelovac, D., & Armstrong, D. K. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20113 · Cited by 765
Hennessy, B. T., Coleman, R. L., & Markman, M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61338-6 · Cited by 640
Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., Volgger, B., Vergote, I., Pignata, S., Ferrero, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7519 · Cited by 575
Self-citationPEGylated liposomes: immunological responses
Mohamed, M., Abu Lila, A. S., Shimizu, T., Alaaeldin, E., Hussein, A., Sarhan, H. A., Szebeni, J., & Ishida, T. (2019) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2019.1627174 · Cited by 523
Latest research and treatment of advanced-stage epithelial ovarian cancer
Coleman, R. L., Monk, B. J., Sood, A. K., & Herzog, T. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.5 · Cited by 489
Metadata
- Authors
- Ferrandina, G., Ludovisi, M., Lorusso, D., Pignata, S., Breda, E., Savarese, A., Del Medico, P., Scaltriti, L., Katsaros, D., Priolo, D., & Scambia, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-02-20
- Volume
- 26
- Issue
- 6
- Pages
- 890-896
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2133506440
- Cited by
- 289
- References
- 28
- FWCI
- 25.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.